leisure time -WSS

leisure time

author：entertainment 2025-09-28 00:53:21 - browse：81

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Why Medicare shouldn’t cover every FDA

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

FTC sues over Novant Health acquisition of two N.C. hospitals

Leading voice in opioid treatment defends methadone clinic system

Health AI adoption puts security, privacy startups on investors' radar

Gene editing the human germline: What are the risks?

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

focus

leisure time

leisure time

The high cost of giving birth even with insurance

Baby aspirin cuts fat buildup in liver disease patients, in small study

Dobbs anniversary: the lost opportunity of abortion as health care

Syphilis numbers in the United States reach record heights

Medical leaders decry Supreme Court decision on affirmative action

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Trump demands the U.S. pay no more for drugs than other countries … again

Merck CEO won’t testify in Senate, citing no expertise in drug prices

State Dept. review finds Biden bears some blame for Afghanistan failures

CVS Caremark has created a new ploy: the drug ‘rebate credit’

focus

Orchard's therapy for neuron disease in children wins FDA approval

Investment in vaccine development is lagging, report finds

U.K. researchers warn about biases in medical devices, algorithms

Zyn nicotine pouches become unlikely player in latest culture war

New clues to why women have higher risk of autoimmune disorders

Intermittent fasting comes with a heart risk? Not so fast

entertainment

entertainment

focus

hotspot